HALIX Joins Consortium of Partners to Provide GMP Services for COVID-19 Vaccine
Dutch company HALIX has announced it is joining a consortium of partners that are all under the guidance of the University of Oxford to provide good manufacturing practice (GMP) manufacturing services for a COVID-19 vaccine.
Dutch company HALIX has announced it is joining a consortium of partners that are all under the guidance of the University of Oxford to provide good manufacturing practice (GMP) manufacturing services for a COVID-19 vaccine.
The alliance will support the large-scale production of a COVID-19 vaccine that is currently under development at the University of Oxford’s Jenner Institute. As part of the collaboration, HALIX will use its GMP facilities, applying its viral vector bioprocessing expertise, to transfer an industrial scale drug substance from Pall in the United Kingdom. Through the ability to manufacture at a larger scale, it is possible that the time to make the vaccine available for deployment could be decreased.
In an April 15, 2020 press release, Alex Huybens, chief operations officer of HALIX, said, “We are committed to working as one team across the industry bringing our collective expertise, track record, and manufacturing capabilities, to support the Jenner Institute’s rapid clinical development of this nCoV-19 vaccine candidate to combat this evolving crisis as quickly as possible.”
Source: HALIX
INTERPHEX 2025: Use of Walk-In Chambers for Bio/Pharma Development and Manufacturing
April 2nd 2025Sitting down with the PharmTech Group at INTERPHEX 2025, Christopher Murphy, director of Global Business Development and Service Customer Support at Environmental Specialties, discusses the design and critical role of walk-in chambers in the bio/pharmaceutical industry.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
